The artificial medium-chain triglyceride triheptanoin has actually shown potential to bring back brain energy and decrease caudate atrophy in Huntington disease, and improved motor function for as much as a year, according to data provided at the International Congress of Parkinsons Disease and Motion Disorders.
Dr Fanny Mochel
Utilizing a placebo control group from an external research study of patients with Huntingtons disease with what Mochel described as “similar scientific attributes,” she stated the research study confirmed TMS clinical stability in treated clients at 1 year (2.6 ± 4.6 vs 0.6 ± 5.1; P =.057) and found substantially lower caudate atrophy (– 3% vs– 6.7%, compared with baseline; P < TRIHEP3 randomized 100 clients with early phase Huntington disease to triheptanoin 1g/kg day-to-day and placebo. It followed on previous research in which the group used 31-phosphorus brain MR spectroscopy to demonstrate triheptanoin brought back a typical brain energetic profile in patients with Huntingtons illness. TRIHEP3 was a 6-month randomized controlled trial at two centers, followed by a 6-month open-label stage. After that, 42 clients decided to take part in the 1-year extension research study. TRIHEP3 found no distinction in caudate limit shift integral (cBSI) at 6 months-- the primary endpoint. In the extension study, TMS tended to support in clients treated for 1 year (0.6 ± 5.1), compared with those treated for 6 months (2.5 ± 4.5; P =.072). Reporting results of TRIHEP3 and an extension research study, Fanny Mochel, MD, PhD, of Sorbonne University in Paris and the Paris Brain Institute, said in an interview that her group is the only one investigating triheptanoin to target caudate atrophy in Huntingtons illness. The Food and Drug Administration last year approved triheptanoin for the treatment of long-chain fat oxidation conditions. " The main findings are two observations: that clients were clinically steady based upon their gradation of overall motor rating (TMS) on UHDRS (Unified Huntingtons Disease Rating Scale) after 1 year," Mochel stated in an interview. "The other is that we observed a decrease of the caudate atrophy development that we generally see over 1 year by about 50%.".